Market Research Future provides premium research reports that are relevant across all
sectors. Recently published “Epigenetics Market Research Report – Forecast to 2023”
provides analysis of factors pertinent to market growth. Expert data analysts take a
magnifying glass to the various nuances of the market in an effort to impart put forth fresh
content which is vital in assisting organizations to make major business decisions
Key Vendors Operating In the Global Epigenetics Market:
Bio-Rad (US), Illumina (US), QIAGEN (Netherlands), Thermo Fisher (US), Active Motif (US),
Diagenode (Belgium), Agilent (US), Merck Millipore (US), Abcam (UK), New England Biolabs
(US), PerkinElmer (US), Zymo Research (US), and others.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6161 .
Market Scenario:
Epigenetics is the study of heritable changes in gene function not involving changes in the
DNA sequence such as changes in a chromosome, phenotypic affecting gene activity and
expression. The sources of heritable changes may be external from environmental factors,
or internal factors such as age, disease and others. Examples of Epigenetics are DNA
methylation and histone modification, which alters genes expression without altering the
DNA sequence.
The market drivers of Epigenetics are growing risk factors and the associated increase in
cases of cancer, increase in the R&D activities, developing pharmaceutical, and
biotechnology sectors, application expanse of epigenetics and others. The development of
high sensitive and selective tests, instrumentation and a concurrent rise in computational
power is driving a massive adoption. The advancements such as the development of DNA
and RNA modifying enzymes such as acetylases, methyltransferases, reverse transcriptase,
ligases, and other protein-modifying enzymes has generated tremendous enthusiasm and
concurrent faster market adoption.
The growing government support for biotechnology and growing partnership between
academia and industry is another driver of growth. Attractive and critical advantages of
technology exemplified by high-throughput molecular analysis of tissues, such as quick,
cost-effective, efficient for less labor intensive and requires a lesser number of steps are the
operational and economic driving factors of the market. Other technological developments
include automation, advances in PCR technology, strategic and cross-functional nature of
the molecular diagnostic technology and others.
High growth of biotech and growing number of start-ups are driving the development of
proprietary technology. According to national venture capital association, the Biotechnology
industry received the second largest amount of venture capital for the year 2016 and ended
with a 17% rise in dollars as compared with the previous year.
The prime market constraints include prohibitive costs of molecular diagnostics, ha high cost
of manufacturing, consolidated nature of the market has put a premium on the price other f
the epigenetics products, nascent stage of technology and high power of firms relative to
buyers.
Segments:
The Global Epigenetics Market is segmented based on instruments, consumables,
applications, technology, end users, and regions.
Based on instruments, the market comprises of NGS, spectrometer, PCR, software solutions
and others.
Based on consumables, the market comprises of kit, enzymes, reagent, and others.
Based on application, the market comprises of oncology, developmental biology, drug
discovery, cardiology, immunology, and others.
Based on technology, the market comprises of methylation, histone modification, and
others.
Based on end users the market is segmented into academia and research, pharmaceutical
and biotechnology industry and others.